Valproic Acid
Wolfram Syndrome
University of BirminghamSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Wolfram Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Depakine Centre d'Etude des Cellules Souches | Phase 2 | CCC |
Tirzepatide Ospedale San Raffaele | Phase 2 | CCC |
TAURURSODIOL Amylyx Pharmaceuticals Inc. | Phase 2 | CCC |
Dantrolene Washington University School of Medicine | Phase 1/2 | CCC |
Exenatide Hadassah Medical Organization | N/A | D |
Same molecule, other indications
Valproic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →